Skip to main content
HT

Hirsh Trivedi

Dr Hirsh Trivedi**lean Masld Risk**fib-4 Score Screening**meal Timing and Liver Fat**exercise and Liver Fat Independence
1episode
1podcast

We have 1 summarized appearance for Hirsh Trivedi so far. Browse all podcasts to discover more episodes.

Featured On 1 Podcast

Top resources Hirsh Trivedi mentions

Books, tools, and gear cited across podcast appearances. Ranked by frequency.

SignalCast may earn commission on purchases via affiliate links on each resource page.

All Appearances

1 episode

AI Summary

→ WHAT IT COVERS Dr Hirsh Trivedi, transplant hepatologist, explains how metabolic dysfunction-associated steatotic liver disease (MASLD) develops silently in people with normal BMI, how liver fat progresses through four fibrosis stages toward cirrhosis, and which specific lifestyle interventions — meal timing, exercise type, sleep quality, and diet composition — can reverse scarring before pharmaceutical intervention becomes necessary. → KEY INSIGHTS - **Lean MASLD Risk:** 15–20% of people with fatty liver disease have a normal BMI, a condition called lean MASLD. South Asian and Hispanic populations carry elevated genetic risk due to specific polymorphisms. These individuals often lack classic metabolic markers like elevated blood glucose yet still face accelerated cardiovascular risk equivalent to obese MASLD patients. Checking fasting insulin and calculating HOMA-IR can detect evolving insulin resistance 10–15 years before a type 2 diabetes diagnosis appears on standard bloodwork. - **FIB-4 Score Screening:** A simple calculator called the FIB-4 score, derived from standard blood panel results, estimates liver fibrosis risk without a biopsy. A score below 1.3 indicates low fibrosis risk manageable in primary care. Scores above 1.3 require specialist referral and secondary fibrosis testing. Most primary care visits already include the labs needed to calculate this score, making it a zero-cost first screening step anyone can request at their next appointment. - **Meal Timing and Liver Fat:** Skipping breakfast and eating a large late dinner is associated with a 50% higher risk of developing MASLD, independent of total caloric intake. Insulin sensitivity follows a circadian rhythm, peaking earlier in the day. Eating the largest meals at breakfast and lunch, finishing dinner at least three hours before sleep, and avoiding late-night eating allows the liver to enter its nocturnal restorative phase without being burdened by excess glucose metabolism. - **Exercise and Liver Fat Independence:** Exercise reduces liver fat and inflammation independent of weight loss, confirmed through liver biopsy studies and animal models. Muscle contractions release myokines — specifically irisin and interleukin-6 — that travel directly to the liver and reduce hepatic fat accumulation and inflammation. A short walk after meals reduces the glucose load reaching the liver, lowering de novo lipogenesis. Even brief exercise snacks throughout a sedentary workday contribute meaningfully to total metabolic benefit. - **Weight Loss Thresholds for Fibrosis Reversal:** A 5% reduction in body weight produces measurable liver defatting. Reaching 7–10% weight loss can begin reversing liver fibrosis — scarring previously considered permanent. Bariatric surgery and semaglutide data both confirm this reversal is achievable. Semaglutide is currently the only GLP-1 FDA-approved specifically for MASLD in patients with stage 2–3 fibrosis. Tirzepatide shows similar liver benefits but lacks FDA approval for this indication as of the episode recording. - **GLP-1 Discontinuation Risk:** Only 10–15% of patients remain on GLP-1 medications after one year due to insurance coverage loss and side effects. Upon discontinuation, patients typically regain weight within 12 months, but the regained mass skews toward fat rather than lean tissue, leaving them in a worse metabolic state than before starting treatment. Dr Trivedi recommends pairing every GLP-1 prescription with a structured resistance training program and adequate protein intake to preserve muscle during and after treatment. - **Sleep Apnea and Liver Inflammation:** Obstructive sleep apnea creates repeated nocturnal hypoxic episodes that generate reactive oxygen species and local liver inflammation, directly worsening MASLD independent of diet or weight. Dr Trivedi screens MASLD patients for sleep apnea by asking about snoring, morning fatigue, and checking for relative erythrocytosis on bloodwork. He reports that virtually every MASLD patient he sees reports sleep disturbances, yet sleep is rarely addressed by prior treating physicians, making it a consistently overlooked intervention point. → NOTABLE MOMENT Dr Trivedi describes a preclinical mouse study where researchers removed the weight-loss effect of semaglutide entirely and still observed measurable improvement in liver fat accumulation through liver sinusoidal endothelial cells. This suggests GLP-1 medications may act directly on liver tissue through a mechanism completely separate from weight reduction, potentially reshaping how these drugs are understood and prescribed. 💼 SPONSORS [{"name": "38 Terra", "url": "https://38terra.com"}, {"name": "Function Health", "url": "https://functionhealth.com/simonhill"}, {"name": "iAM8 Health", "url": "https://iamatehealth.com"}, {"name": "Shokz", "url": "https://shokz.com"}, {"name": "WHOOP", "url": "https://join.whoop.com/simon"}] 🏷️ Fatty Liver Disease, Insulin Resistance, Liver Fibrosis, GLP-1 Medications, Metabolic Health, Sleep and Metabolism, Exercise and Liver Health

Explore More

Never miss Hirsh Trivedi's insights

Subscribe to get AI-powered summaries of Hirsh Trivedi's podcast appearances delivered to your inbox weekly.

Start Free Today

No credit card required • Free tier available